Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone

Objective. Serous retinal detachment (SRD) is a common anatomical complication associated with dome-shaped macula (DSM) and staphyloma margin in myopic patients. Here we described the anatomical and functional outcomes obtained with the use of oral spironolactone, a mineralocorticoid antagonist, in...

Full description

Saved in:
Bibliographic Details
Main Authors: Álvaro Fernández-Vega Sanz, Carlos Mario Rangel, Eva Villota Deleu, Beatriz Fernández-Vega Sanz, Ronald Mauricio Sánchez-Ávila
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2016/8491320
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832556489174155264
author Álvaro Fernández-Vega Sanz
Carlos Mario Rangel
Eva Villota Deleu
Beatriz Fernández-Vega Sanz
Ronald Mauricio Sánchez-Ávila
author_facet Álvaro Fernández-Vega Sanz
Carlos Mario Rangel
Eva Villota Deleu
Beatriz Fernández-Vega Sanz
Ronald Mauricio Sánchez-Ávila
author_sort Álvaro Fernández-Vega Sanz
collection DOAJ
description Objective. Serous retinal detachment (SRD) is a common anatomical complication associated with dome-shaped macula (DSM) and staphyloma margin in myopic patients. Here we described the anatomical and functional outcomes obtained with the use of oral spironolactone, a mineralocorticoid antagonist, in the management of myopic patients with SRD associated with DSM and staphyloma margin. Methods. We evaluated both eyes of twelve myopic patients with long-standing SRD associated with DSM or staphyloma margin. The patients were treated daily for six months with oral spironolactone 50 mg. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT), determined by optical coherence tomography, were evaluated on the first day and on monthly follow-up visits. Results. Pretreatment BCVA (mean ± standard deviation) was 0.406 ± 0.324 LogMAR, and posttreatment BCVA was 0.421 ± 0.354 LogMAR (P=0.489). Pretreatment CRT was 323.9 ± 78.6 μm, and after six months of treatment it was significantly lower, 291.2 ± 74.5 μm (P=0.010). There were no treatment-related complications. Conclusions. We evaluated a novel treatment for SRD associated with DSM and staphyloma margin in myopic patients. After six months of treatment with the mineralocorticoid antagonist spironolactone, the subretinal fluid and CRT were significantly reduced; however, there was no improvement in BCVA.
format Article
id doaj-art-a70e886d881f467faa15e6435ed039cc
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-a70e886d881f467faa15e6435ed039cc2025-02-03T05:45:15ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/84913208491320Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with SpironolactoneÁlvaro Fernández-Vega Sanz0Carlos Mario Rangel1Eva Villota Deleu2Beatriz Fernández-Vega Sanz3Ronald Mauricio Sánchez-Ávila4Instituto Oftalmológico Fernández-Vega, 33012 Oviedo, SpainInstituto Oftalmológico Fernández-Vega, 33012 Oviedo, SpainInstituto Oftalmológico Fernández-Vega, 33012 Oviedo, SpainInstituto Oftalmológico Fernández-Vega, 33012 Oviedo, SpainInstituto Universitario Fernández-Vega, Universidad de Oviedo, Oviedo, SpainObjective. Serous retinal detachment (SRD) is a common anatomical complication associated with dome-shaped macula (DSM) and staphyloma margin in myopic patients. Here we described the anatomical and functional outcomes obtained with the use of oral spironolactone, a mineralocorticoid antagonist, in the management of myopic patients with SRD associated with DSM and staphyloma margin. Methods. We evaluated both eyes of twelve myopic patients with long-standing SRD associated with DSM or staphyloma margin. The patients were treated daily for six months with oral spironolactone 50 mg. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT), determined by optical coherence tomography, were evaluated on the first day and on monthly follow-up visits. Results. Pretreatment BCVA (mean ± standard deviation) was 0.406 ± 0.324 LogMAR, and posttreatment BCVA was 0.421 ± 0.354 LogMAR (P=0.489). Pretreatment CRT was 323.9 ± 78.6 μm, and after six months of treatment it was significantly lower, 291.2 ± 74.5 μm (P=0.010). There were no treatment-related complications. Conclusions. We evaluated a novel treatment for SRD associated with DSM and staphyloma margin in myopic patients. After six months of treatment with the mineralocorticoid antagonist spironolactone, the subretinal fluid and CRT were significantly reduced; however, there was no improvement in BCVA.http://dx.doi.org/10.1155/2016/8491320
spellingShingle Álvaro Fernández-Vega Sanz
Carlos Mario Rangel
Eva Villota Deleu
Beatriz Fernández-Vega Sanz
Ronald Mauricio Sánchez-Ávila
Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
Journal of Ophthalmology
title Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
title_full Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
title_fullStr Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
title_full_unstemmed Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
title_short Serous Retinal Detachment Associated with Dome-Shaped Macula and Staphyloma Edge in Myopic Patients before and after Treatment with Spironolactone
title_sort serous retinal detachment associated with dome shaped macula and staphyloma edge in myopic patients before and after treatment with spironolactone
url http://dx.doi.org/10.1155/2016/8491320
work_keys_str_mv AT alvarofernandezvegasanz serousretinaldetachmentassociatedwithdomeshapedmaculaandstaphylomaedgeinmyopicpatientsbeforeandaftertreatmentwithspironolactone
AT carlosmariorangel serousretinaldetachmentassociatedwithdomeshapedmaculaandstaphylomaedgeinmyopicpatientsbeforeandaftertreatmentwithspironolactone
AT evavillotadeleu serousretinaldetachmentassociatedwithdomeshapedmaculaandstaphylomaedgeinmyopicpatientsbeforeandaftertreatmentwithspironolactone
AT beatrizfernandezvegasanz serousretinaldetachmentassociatedwithdomeshapedmaculaandstaphylomaedgeinmyopicpatientsbeforeandaftertreatmentwithspironolactone
AT ronaldmauriciosanchezavila serousretinaldetachmentassociatedwithdomeshapedmaculaandstaphylomaedgeinmyopicpatientsbeforeandaftertreatmentwithspironolactone